<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248531</url>
  </required_header>
  <id_info>
    <org_study_id>HS0001</org_study_id>
    <secondary_id>2017-000892-10</secondary_id>
    <nct_id>NCT03248531</nct_id>
  </id_info>
  <brief_title>A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.</brief_title>
  <official_title>A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses
      and scarring on the skin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>HiSCR is defined as at least a 50% reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining fistula count.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab plasma concentration at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood samples will be taken to determine Bimekizumab plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab plasma concentration at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Blood samples will be taken to determine Bimekizumab plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab plasma concentration at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Blood samples will be taken to determine Bimekizumab plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab plasma concentration at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Blood samples will be taken to determine Bimekizumab plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab plasma concentration at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Blood samples will be taken to determine Bimekizumab plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab plasma concentration at Week 30</measure>
    <time_frame>Week 30</time_frame>
    <description>Blood samples will be taken to determine Bimekizumab plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AE)</measure>
    <time_frame>From Screening to Safety Follow-Up (Week 30)</time_frame>
    <description>An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug (medicinal product). The event does not necessarily have a causal relationship with that treatment or usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events categorized by severity</measure>
    <time_frame>From Screening to Safety Follow-Up (Week 30)</time_frame>
    <description>An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug (medicinal product). The event does not necessarily have a causal relationship with that treatment or usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>From Screening to Safety Follow-Up (Week 30)</time_frame>
    <description>A SAE is any untoward medical occurrence that at any dose:
Results in death
Is life-threatening
Requires in patient hospitalization or prolongation of existing hospitalisation
Is a congenital anomaly or birth defect
Is as infection that requires treatment parenteral antibiotics
Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAEs) categorized by severity</measure>
    <time_frame>From Screening to Safety Follow-Up (Week 30)</time_frame>
    <description>A SAE is any untoward medical occurrence that at any dose:
Results in death
Is life-threatening
Requires in patient hospitalization or prolongation of existing hospitalisation
Is a congenital anomaly or birth defect
Is as infection that requires treatment parenteral antibiotics
Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects withdrawing due to Adverse Events</measure>
    <time_frame>From Screening to Safety Follow-Up (Week 30)</time_frame>
    <description>An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug (medicinal product). The event does not necessarily have a causal relationship with that treatment or usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in vital signs (blood pressure [BP])</measure>
    <time_frame>From Screening until Safety Follow-Up (Week 30)</time_frame>
    <description>Vital signs will be collected at pre-specified visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in vital signs (pulse rate)</measure>
    <time_frame>From Screening until Safety Follow-Up (Week 30)</time_frame>
    <description>Vital signs will be collected at pre-specified visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in body weight</measure>
    <time_frame>From Screening until Safety Follow-Up (Week 30)</time_frame>
    <description>Body weight will be collected at pre-specified visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ECG parameters</measure>
    <time_frame>From Screening until Safety Follow-Up (Week 30)</time_frame>
    <description>Twelve-lead standard ECGs will be recorded at pre-specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline hematology parameter</measure>
    <time_frame>From Screening until Safety Follow-Up (Week 30)</time_frame>
    <description>Laboratory parameters will be collected at pre-specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in biochemistry parameter</measure>
    <time_frame>From Screening until Safety Follow-Up (Week 30)</time_frame>
    <description>Laboratory parameters will be collected at pre-specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in urinalysis parameter</measure>
    <time_frame>From Screening until Safety Follow-Up (Week 30)</time_frame>
    <description>Laboratory parameters will be collected at pre-specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in physical examination</measure>
    <time_frame>From Screening until Safety Follow-Up (Week 30)</time_frame>
    <description>Physical examination will be performed at pre-specified visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab Anti-drug antibody (ADA) concentration at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood samples will be taken to determine the Bimekizumab ADA concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab Anti-Drug Antibody (ADA) concentration at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Blood samples will be taken to determine the Bimekizumab ADA concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab Anti-Drug Antibody (ADA) concentration at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Blood samples will be taken to determine the Bimekizumab ADA concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab Anti-Drug Antibody (ADA) concentration at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Blood samples will be taken to determine the Bimekizumab ADA concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab Anti-Drug Antibody (ADA) concentration at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Blood samples will be taken to determine the Bimekizumab ADA concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bimekizumab Anti-Drug Antibody (ADA) concentration at Week 30</measure>
    <time_frame>Week 30</time_frame>
    <description>Blood samples will be taken to determine the Bimekizumab ADA concentration.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Bimekizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive several placebo applications to keep the blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimekizumab</intervention_name>
    <description>Bimekizumab in different dosages (dose 1 and 2).</description>
    <arm_group_label>Bimekizumab</arm_group_label>
    <other_name>UCB4940</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab in different dosages (dose 1, 2 and 3).</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <other_name>Humira®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be provided matching Bimekizumab.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (18 to 70 years of age, inclusive) must have a diagnosis of HS for at
             least

             1 year prior to Baseline

          -  Stable HS for at least 2 months prior to Screening and also at the Baseline Visit

          -  Inadequate response to at least a 3-month study of an oral antibiotic for treatment of
             HS

          -  Total abscess and inflammatory nodule count &gt;=3 at the Baseline Visit

          -  Subject must agree to daily use (and throughout the entirety of the study) of 1
             pre-specified over-the-counter topical antiseptics on their HS lesions

          -  Female subjects must be postmenopausal, permanently sterilized or, if of childbearing
             potential, must be willing to use a highly effective method of contraception up till
             20 weeks after last administration of study drug and have a negative pregnancy test at
             Visit 1 (Screening) and immediately prior to first dose

          -  Male subjects must be willing to use a method of contraception when sexually active,
             up till 20 weeks after the last administration of study medication

        Exclusion Criteria:

          -  Prior treatment with anti-IL17s or participation in an anti-IL17 study

          -  Previously received anti-TNFs

          -  Subject requires, or is expected to require, opioid analgesics for any reason
             (excluding tramadol)

          -  Subject received prescription topical therapies for the treatment of HS within 14 days
             prior to the Baseline Visit

          -  Subject received systemic non-biologic therapies for HS with potential therapeutic
             impact for HS less than 28 days prior to Baseline Visit

          -  Draining fistula count &gt;20 at the Baseline Visit

          -  Diagnosis of inflammatory conditions other than HS
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1-844-599-2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>+1844599</phone>
    <phone_ext>2273</phone_ext>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hs0001 121</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 119</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 111</name>
      <address>
        <city>Orange</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 117</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 112</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 113</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 115</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 125</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 123</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 118</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 124</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 120</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 103</name>
      <address>
        <city>East Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 101</name>
      <address>
        <city>Fremantle</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 104</name>
      <address>
        <city>Saint Leonards</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 100</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 102</name>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 200</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 203</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 202</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 301</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 300</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 302</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 408</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 405</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 407</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 400</name>
      <address>
        <city>Dessau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 403</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 404</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 402</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 406</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 503</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 701</name>
      <address>
        <city>Harstad</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 700</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 901</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 902</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 903</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hs0001 900</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hidradenitis Suppurativa</keyword>
  <keyword>Bimekizumab</keyword>
  <keyword>HS</keyword>
  <keyword>Moderate to Severe HS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

